HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated ... such as cytokines and checkpoint ...

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics ... such as cytokines; and PROBODY platform in preclinical ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Another bsAbs targeting EGFR and CD3 is CX-904, developed by CytomX, which is an investigational Probody therapy, designed as a masked, conditionally activated T-cell engager ... IL-4, a ...

This innovative therapy aims to enhance anti-tumor efficacy by inducing a strong localized immu CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual ...

A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants Lead tribody IM1240 data demonstrated that cytokine release is ...